Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care

Prenatal Diagnosis

Volumn 34, Issue 5, 2014, Pages 409-415

  Banch Clausen, Frederik ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY; RHESUS D ANTIGEN; BLOOD GROUP ANTIGEN;

BLOOD GROUP; CLINICAL PRACTICE; FALSE NEGATIVE RESULT; FETUS BLOOD; HUMAN; IMMUNIZATION; NEWBORN HEMOLYTIC DISEASE; NON INVASIVE PROCEDURE; PREDICTION; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRENATAL PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SCREENING; UMBILICAL CORD BLOOD; CHEMISTRY; ERYTHROBLASTOSIS, FETAL; FEMALE; FETUS; NEWBORN; POLYMERASE CHAIN REACTION; PRENATAL DIAGNOSIS; PROCEDURES;

BLOOD GROUP ANTIGENS; ERYTHROBLASTOSIS, FETAL; FEMALE; FETAL BLOOD; FETUS; HUMANS; INFANT, NEWBORN; POLYMERASE CHAIN REACTION; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS;

EID: 84898825445     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4326     Document Type: Review

References (95)

1. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012;18:1041-51.
2. Simpson JL. Cell-free fetal DNA and maternal serum analytes for monitoring embryonic and fetal status. Fertil Steril 2013;99:1124-34.
3. Hill M, Barrett AN, White H, Chitty LS. Uses of cell free fetal DNA in maternal circulation. Best Pract Res Clin Obstet Gynaecol 2012;26:639-54.
4. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
5. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA. A systematic review and meta-analysis. JAMA 2011;306:627-36.
6. Faas BHW, Beuling EA, Christiaens GCML, et al. Detection of fetal RHD-specific sequences in maternal plasma. Lancet 1998;352:1196.
7. Lo YMD, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998;339:1734-8.
8. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002;42:1079-85.
9. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009;29:101-7.
10. Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood-a meta-analysis. Am J Obstet Gynecol 2006;195:1163-73.
11. Legler TJ, Müller SP, Haverkamp A, et al. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother 2009;36:189-98.
12. Scheffer PG, de Haas M, van der Schoot CE. The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol 2011;18:467-73.
13. Daniels G, van der Schoot CE, Olsson ML. Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang 2011;101:327-32.
14. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012;52:752-8.
15. Dziegiel MH. Noninvasive prenatal screening for RHD: the 1st national antenatal directed anti-D prophylaxis program - the Danish model or a guide to robust prediction of need of anti-D. ISBT Science Series 2012;7:160-3.
16. de Haas M, van der Ploeg CPB, Scheffer PG, et al. A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D. ISBT Science Series 2012;7:164-7.
17. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120:227-34.
18. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000;14:44-61.
19. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008;13:207-14.
20. Urbaniak SJ. The scientific basis of antenatal prophylaxis. BJOG 1998;105(Supplement 18):11-8.
21. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978;118:623-7.
22. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J 1978;118:627-30.
23. Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;48:1721-9.
24. Turner RM, Lloyd-Jones M, Anumba DO, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One 2012;7:e30711:1-10.
25. Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation - outcome of a new antenatal screening and prevention program. PLoS One 2013;8:e70984:1-7.
26. Colin Y, Chérif-Zahar B, Le Van Kim C, et al. Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis. Blood 1991;78:2747-52.
27. Daniels G. Variants of RhD - current testing and clinical consequences. Br J Haematol 2013;161:461-70.
28. Okuda H, Suganuma H, Kamesaki T, et al. The analysis of nucleotide substitutions, gaps, and recombination events between RHD and RHCE genes through complete sequencing. Biochem Biophys Res Commun 2000;274:670-83.
29. Wagner FF, Flegel WA. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology 2004;20:23-36.
30. Tsui NB, Hyland CA, Gardener GJ, et al. Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3+1G>A) allele. Prenat Diagn 2013;33:1214-6. DOI: 10.1002/pd.4230.
31. van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003;17:31-44.
32. Tynan JA, Angkachatchai V, Ehrich M, et al. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. Am J Obstet Gynecol 2011;204:251.e1-6.
33. Wang XD, Wang BL, Ye SL, et al. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest 2009;39: 607-17.
34. Haer-Wigman L, Veldhuisen B, Jonkers R, et al. RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion 2013;53:1559-74.
35. Minon J-M, Gerard C, Senterre J-M, et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008;48:373-81.
36. Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008;336:816-8.
37. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75.
38. Birch L, English CA, O'Donoghue K, et al. Accurate and robust quantification of ciculating fetal and total DNA in maternal plasma from 5 to 41weeks of gestation. Clin Chem 2005;51:312-20.
39. Zhou L, Thorson JA, Nugent C, et al. Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. Am J Obstet Gynecol 2005;193:1966-71.
40. Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-8.
41. Tynan JA, Mahboubi P, Cagasan LL, et al. Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma. J Mol Diagn 2011;13:382-9.
42. Doescher A, Petershofen EK, Wagner FF, et al. Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. Transfusion 2013;53:353-62.
43. Hyland CA, Gardener GJ, Davies H, et al. Evaluation of non-invasive prenatal RHD genotyping of the fetus. Med J Aust 2009;191:21-5.
44. Li Y, Kazzaz JA, Kellner LH, Brown SA. Incorporation of fetal DNA detection assay in a noninvasive RhD diagnostic test. Prenat Diagn 2010;30:1010-2.
45. Zejskova L, Jancuskova T, Kotlabova K, et al. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma-next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol 2010;89:241-7.
46. Kolialexi A, Tounta G, Apostolou P, et al. Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. Eur J Obstet Gynecol Reprod Biol 2012;161:34-7.
47. White HE, Dent CL, Hall VJ, et al. Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis. PLoS One 2012;7:e45073:1-15.
48. Moise KJ Jr, Boring NH, O'Shaughnessy R, et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn 2013;33:95-101.
49. Cardo L, García BP, Alvarez FV. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010;48: 1121-6.
50. Daniels G, Finning K, Wade A, et al. Implementation of routine of fetal RHD typing in all RHD-negative pregnant women: timing, costs, and efficiency. Vox Sang 2012;103(suppl. 1):34.
51. Akolekar R, Finning K, Kuppusamy R, et al. Fetal RHD genotyping in maternal plasma at 11-13weeks of gestation. Fetal Diagn Ther 2011;29:301-6.
52. Bombard AT, Akolekar R, Farkas DH, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011;31:802-8.
53. Maddocks DG, Alberry MS, Attilakos G, et al. The SAFE project: towards non-invasive prenatal diagnosis. Biochem Soc Trans 2009;37:460-5.
54. Dovč-Drnovšek T, Klemenc P, Toplak N, et al. Reliable determination of fetal RhD status by RHD genotyping from maternal plasma. Transfus Med Hemother 2013;40:37-43.
55. Macher HC, Noguerol P, Medrano-Campillo P, et al. Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta 2012;413:490-4.
56. van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006;13:53-7.
57. Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008;48:2292-301.
58. Grande M, Ordoñez E, Cirigliano V, et al. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. Prenat Diagn 2013;33:173-8.
59. Legler TJ, Liu Z, Mavrou A, et al. Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn 2007;27:824-9.
60. Lui YYN, Lo YMD. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med 2002;40:962-8.
61. Barrett AN, Zimmermann BG, Wang D, et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One 2011;6:e25202:1-8.
62. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-30.
63. Clausen FB, Jakobsen TR, Rieneck K, et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS One 2013;8:e76990:1-8.
64. Müller SP, Bartels I, Stein W, et al. Cell-free fetal DNA in specimen from pregnant women is stable up to 5days. Prenat Diagn 2011;31:1300-4.
65. de Haas M, van der Schoot E. Prenatal screening. ISBT Sci Ser 2013;8:6-10.
66. Damkjaer MB, Perslev A, Clausen FB, et al. Study of compliance with a new, targeted antenatal D immunization prevention programme in Denmark. Vox Sang 2012;103:145-9.
67. Koby L, Grunbaum A, Benjamin A, et al. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis? J Obstet Gynaecol Can 2012;34:429-35.
68. Oxenford K, Silcock C, Hill M, Chitty L. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women. Prenat Diagn 2013;33:688-94.
69. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11:5:1-8.
70. Benachi A, Delahaye S, Leticee N, et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012;162:28-32.
71. Hawk AF, Chang EY, Shields SM, Simpson KN. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013;122:579-85.
72. Goodspeed TA, Allyse M, Sayres LC, et al. Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing. Trends Biotechnol 2013;31:7-9.
73. Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011;118:1340-8.
74. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004;8:23-31.
75. Brojer E, Zupanska B, Guz K, et al. Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. Transfusion 2005;45:1473-80.
76. Clausen FB, Krog GR, Rieneck K, et al. Reliable test for prenatal prediction of fetal RhD type using maternal plasma from RhD negative women. Prenat Diagn 2005;25:1040-4.
77. Rouillac-Le Sciellour C, Sérazin V, Brossard Y, et al. Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD. Transfus Clin Biol 2007;14:572-7.
78. Tounta G, Vrettou C, Kolialexi A, et al. A multiplex PCR for Non-invasive fetal RHD genotyping using cell-free foetal DNA. In Vivo 2011, 25:100-4.
79. Daniels G, Finning K, Martin P. Noninvasive fetal blood grouping: present and future. Clin Lab Med 2010;30:431-42.
80. Amaral DR, Credidio DC, Pellegrino J Jr, Castilho L. Fetal RHD genotyping by analysis of maternal plasma in a mixed population. J Clin Lab Anal 2011;25:100-4.
81. Martin FO, de Menezes SS, Chiba AK, et al. RHD gene polymorphisms in alloimmunized RhD-negative individuals with high rate of racial admixture. Transfus Apher Sci 2013;48:113-6.
82. Grootkerk-Tax MG, Soussan AA, de Haas M, et al. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006;46:2142-8.
83. Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009;49:2070-5.
84. Legler TJ. Prenatal rhesus testing. ISBT Science Series 2010;5:7-11.
85. Rath ME, Smits-Wintjens VE, Lindenburg IT, et al. Postnatal outcome in neonates with severe Rhesus c compared to rhesus D hemolytic disease. Transfusion 2013;53:1580-5.
86. Legler TJ, Lynen R, Maas JH, et al. Prediction of fetal Rh D and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. Transfus Apher Sci 2002;27:217-23.
87. Hromadnikova I, Vechetova L, Vesela K, et al. Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies. J Histochem Cytochem 2005;53:301-5.
88. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007;47:2126-33.
89. Li Y, Finning K, Daniels G, et al. Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. Prenat Diagn 2008;28:203-8.
90. Orzińska A, Guz K, Brojer E, Zupańska B. Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c. Prenat Diagn 2008;28:335-7.
91. Gutensohn K, Müller SP, Thomann K, et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. BJOG 2010;117:722-9.
92. Rieneck K, Bak M, Jønson L, et al. Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion 2013. DOI: 10.1111/trf.12172.
93. Jones ML, Wray J, Wight J, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 2004;111:892-902.
94. Maayan-Metzger A, Schwartz T, Sulkes J, Merlob P. Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. Arch Dis Child Fetal Neonatal Ed 2001;84:F60-2.
95. Mathiesen L, Nielsen LK, Andersen JT, et al. Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood 2013;122:1174-81.